文献速递肺结节与肺癌呼吸危重症与机械通气

肺癌相关恶性胸腔积液早期确定性管理的价值

Role of early definitive management for newly diagnosed malignant pleural effusion related to lung cancer.
PubMed 文献 · Respirology · 2020-04-06

该研究回顾2011至2018年首诊即伴恶性胸腔积液的肺癌患者,评估早期胸膜固定或留置胸膜导管等确定性措施的效果。在233例可分析患者中,早期控制措施可降低后续需再次干预的比例,并延长至再次干预的时间,且独立于抗肿瘤治疗。

要点

  • 首诊伴恶性胸腔积液的肺癌患者,早期确定性胸膜干预可减少后续再干预需求。
  • 早期胸膜干预的获益独立于靶向、系统抗肿瘤或最佳支持治疗。
  • 有可靶向突变者中,早期胸膜干预与靶向治疗均独立延长至再干预时间。

核心结论

  • 肺癌相关恶性胸腔积液早期确定性控制措施可减少再干预需求并延长至再干预时间,且独立于抗肿瘤治疗。

研究设计与样本

  • 回顾性随访研究,纳入2011至2018年一家三级医院首诊即伴恶性胸腔积液的肺癌患者,随访至死亡或删失。
  • 筛查509份记录,最终233例符合条件纳入分析。

主要发现

  • 靶向治疗联合早期胸膜干预较单用靶向治疗显著降低后续再干预比例(23.5% vs 53.8%,P=0.002)。
  • 系统抗肿瘤治疗组中早期胸膜干预较未干预降低再干预比例(0% vs 52%,P=0.003)。
  • 最佳支持治疗组中早期胸膜干预较未干预降低再干预比例(18% vs 56.7%,P=0.024)。
  • 可靶向突变组中,早期胸膜干预(HR 0.25,95%CI 0.12-0.53,P<0.001)与靶向治疗(HR 0.22,95%CI 0.10-0.46,P<0.001)均独立与更长至再干预时间相关。

临床怎么用

  • 对首诊即伴恶性胸腔积液的肺癌患者,可考虑在抗肿瘤治疗前或后尽早实施胸膜固定或留置胸膜导管等确定性控制措施。
  • 早期胸膜干预的获益不依赖抗肿瘤治疗类型,靶向、系统治疗或最佳支持治疗人群均可考虑。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: The advent of effective anti-cancer therapy has brought about uncertainty on the benefit of early definitive measures for newly diagnosed MPE from lung cancer. This study aims to investigate the outcomes of MPE in this setting. METHODS: Lung cancer patients with MPE at first presentation to a tertiary care hospital were followed up till death or censored from 2011 to 2018. Early MPE control measures included chemical pleurodesis or IPC before or shortly after oncological treatment. Predictors of time to MPE re-intervention were identified with Cox proportional hazard analyses. RESULTS: Of the 509 records screened, 233 subjects were eligible. One hundred and twenty-seven subjects received oral targeted therapy as first-line treatment and 34 (26.8%) underwent early definitive MPE control measures. Early MPE control measures in addition to targeted therapy, as compared to targeted therapy alone, significantly reduced the subsequent need of MPE re-intervention (23.5% vs 53.8%, P = 0.002). Similar benefits from MPE control measures were found in groups receiving systemic anti-cancer therapy or best supportive care (0% vs 52%, P = 0.003; 18% vs 56.7%, P = 0.024, respectively). In the group with targetable mutations, both early MPE control measures (HR: 0.25, 95% CI: 0.12-0.53, P < 0.001) and the use of targeted therapy (HR: 0.22, 95% CI: 0.10-0.46, P < 0.001) were independently associated with longer time to MPE re-interventions. CONCLUSION: Early MPE control measures in lung cancer has additional benefits on reducing the need and prolonging the time to MPE re-intervention, independent of anti-cancer therapies.

来源:Respirology,查看原文。版权归原作者所有。

引用

  1. Chiang KY, Ho JC, Chong P, et al. Role of early definitive management for newly diagnosed malignant pleural effusion related to lung cancer. Respirology. 2020. PMID: 32249488. doi:10.1111/resp.13812

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。